Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Makedonia, Greece.
1(st) Department of Neurology, Medical School, "AHEPA" General Hospital Medical School, Aristotle University of Thessaloniki, Faculty of Health Sciences, 54124 Thessaloniki, Makedonia, Greece; Greek Association of Alzheimer's Disease and Related Disorders - GAADRD, Greece.
Exp Gerontol. 2021 Jul 15;150:111344. doi: 10.1016/j.exger.2021.111344. Epub 2021 Apr 6.
The daily consumption of Extra Virgin Olive Oil (EVOO) in Mediterranean nutrition is tightly associated with lower frequency of many diseases' appearance, including Alzheimer's disease (AD). Fibrinolytic system is already assumed to be involved in AD pathophysiology through various factors, especially plasminogen activator inhibitor-1 (PAI-1), a2-antiplasmin (α2ΑP) and tissue plasminogen activator (tPA). We, here, present a biochemical study, as a continuation of a clinical trial of a cohort of 84 participants, focusing on the pleiotropic effect of the annual EVOO consumption on the fibrinolytic factors of Mild Cognitive Impairment (MCI) patients. The levels of all these fibrinolytic factors, measured by Enzyme-Linked Immunosorbent Assay (ELISA) method, were reduced in the serum of MCI patients annually administered with EVOO, versus not treated MCI patients, as well as AD patients. The well-established AD hallmarks (Aβ1-40 and Aβ1-42 species, tau, and p-tau) of MCI patients' group, annually administered with EVOO, were restored to levels equal to those of the cognitively-healthy group; in contrast to those patients not being administered, and their AD hallmarks levels increased at the end of the year. Moreover, one of the EVOO annual consumption multimodal effects on the MCI patients focused on the levels of an oxidative stress trademark, malondialdehyde (MDA), which displayed also a visible quenching; On the other hand, an increase exhibited in the MCI patients not consuming EVOO one year after, was attributed to the lack of the EVOO anti-oxidative properties. These outcomes are exploitable towards the establishment of natural products like EVOO, as a preventive remedy fighting this neurodegenerative disorder, AD. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03362996 MICOIL gov Identifier: NCT03362996.
地中海饮食中每天摄入特级初榨橄榄油（EVOO）与许多疾病出现频率降低密切相关，包括阿尔茨海默病（AD）。纤溶系统已被认为通过多种因素参与 AD 病理生理学，特别是纤溶酶原激活物抑制剂-1（PAI-1）、α2-抗纤溶酶（α2ΑP）和组织型纤溶酶原激活物（tPA）。我们在此介绍一项生化研究，作为对 84 名参与者队列进行的临床试验的延续，该研究侧重于每年 EVOO 消耗对轻度认知障碍（MCI）患者纤溶因子的多效作用。通过酶联免疫吸附测定（ELISA）方法测量的所有这些纤溶因子的水平在每年接受 EVOO 治疗的 MCI 患者的血清中降低，与未接受治疗的 MCI 患者以及 AD 患者相比。接受 EVOO 治疗的 MCI 患者组的既定 AD 标志物（Aβ1-40 和 Aβ1-42 种、tau 和 p-tau）恢复到与认知健康组相当的水平；相比之下，未接受治疗的患者其 AD 标志物水平在年底增加。此外，EVOO 对 MCI 患者的年度消费的一种多模式影响之一集中在氧化应激标志物丙二醛（MDA）的水平上，MDA 的水平也明显降低；另一方面，一年后未接受 EVOO 消费的 MCI 患者的 MDA 水平显示出增加，这归因于缺乏 EVOO 的抗氧化特性。这些结果可用于确定 EVOO 等天然产物作为预防这种神经退行性疾病 AD 的方法。临床试验注册：https://clinicaltrials.gov/ct2/show/NCT03362996 MICOIL gov 标识符：NCT03362996。
